Table 2 Univariate and bivariate analyses of HBV infection status and ALT elevation
Analysis model (n = 368) | HBsAg+ vs uninfected | HBsAg–/HBcAb+ vs uninfected | |
|---|---|---|---|
OR (95% CI) | OR (95% CI) | OR (95% CI) | |
Model 1 (univariate analysis): HBV infection status | 5.05 (1.68–15.42) | 0.97 (0.40–2.51) | |
Model 2 (bivariate analysis): HBV infection status adjusted for each confounder: | |||
Sex (female vs male) | 1.21 (0.48–3.26) | 5.03 (1.68–15.28) | 0.96 (0.40–2.48) |
Age (10-year intervals) | 0.81 (0.59–1.11) | 6.41 (1.99–21.57) | 1.29 (0.47–3.77) |
History of elevated ALTa | 9.66 (3.24–28.83) | 4.83 (1.54–15.37) | 0.79 (0.30–2.11) |
Prednisolone | 1.62 (0.62–4.58) | 5.29 (1.75–16.22) | 0.97 (0.40–2.48) |
Methotrexatea | 4.86 (1.58–15.06) | 0.77 (0.30–2.04) | |
Methotrexate alone | 6.95 (1.70–29.65) | ||
Methotrexate + folic acid | 1.17 (0.38–3.82) | ||
Hydroxychloroquine | 0.79 (0.30–2.21) | 4.95 (1.65–15.06) | 0.97 (0.40–2.51) |
Sulfasalazine | 0.66 (0.30–1.48 | 5.48 (1.79–17.14) | 1.02 (0.42–2.65) |
Cyclosporine | 1.05 (0.30–3.05) | 5.02 (1.67–15.29) | 0.97 (0.40–2.51) |
Leflunomide | 0.75 (0.13–2.82) | 5.13 (1.71–15.59) | 0.98 (0.40–2.50) |
Azathioprine | 0.13 (0.01–1.78) | 5.43 (1.80-16.65) | 1.02 (0.42–2.62) |
Methotrexate 6-month accumulated dose | 1.21 (0.89–1.68) | 5.57 (1.82–17.38) | 0.98 (0.41–2.53) |
Methotrexate total accumulated dose | 0.99 (0.96–1.03) | 4.97 (1.65–15.15) | 0.98 (0.40–2.53) |
Prednisolone 6-month accumulated dose | 1.15 (0.64–1.96) | 5.15 (1.70–15.83) | 0.98 (0.40–2.52) |
Prednisolone total accumulated dose | 1.00 (0.94–1.05) | 5.00 (1.67–15.20) | 0.97 (0.40–2.51) |